|Slideshows|May 19, 2022

Must Sees in New Orleans: Things to Check Out During 2022 APA

If you're attending APA 2022 in New Orleans, here are some other things to check out in the city.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Endangered Education: Psychiatric Professional Degrees Under Attack

BySara Sethness, DNP, RN, PMHNP-BC,Lee Moore, DNP, MEd, CRNP-PMH, PMHNP-BC, CNE

June 2nd 2026

Psychiatry Does Not Need a Softer DSM. It Needs a Smarter One.

ByGarrett Rossi, MD

April 30th 2026

Psychedelics Deserve Real Science

ByGarrett Rossi, MD

April 22nd 2026

High-Potency Cannabis: America's New Pastime and Psychiatry's Next Challenge

ByGarrett Rossi, MD

April 16th 2026

When Pills Are Not the Answer: Rethinking the Psychiatrist’s Script

ByGarrett Rossi, MD

April 9th 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Must Sees in New Orleans: Things to Check Out During 2022 APA

Related Content

Endangered Education: Psychiatric Professional Degrees Under Attack

Psychiatry Does Not Need a Softer DSM. It Needs a Smarter One.

Psychedelics Deserve Real Science

High-Potency Cannabis: America's New Pastime and Psychiatry's Next Challenge

When Pills Are Not the Answer: Rethinking the Psychiatrist’s Script

Latest CME

Southern California Psychiatry Conference

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Developing Next-Generation Psychedelic Treatments: Insights on Bretisilocin From AJ Cannon, MD

Artificial Intelligence in Psychopharmacology: Promise and Pitfalls, With Roy Perlis, MD

ALTO-203, an H3 Inverse Agonist, in Depression: Biomarker and Pharmacodynamic Findings

Addressing Sexual Wellness: A Psychiatric Perspective

Monoamines: A Full House